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Background: The body mass index (BMI) is a prognostic factor for chronic obstructive
pulmonary disease (COPD). Despite its importance, little information is available regarding
BMI alteration in COPD from a population-based study. We examined characteristics by BMI
categories in the total and COPD populations in five Latin-American cities, and explored
the factors influencing BMI in COPD.
Methods: COPD was defined as a postbronchodilator forced expiratory volume in the first
second/forced vital capacity (FEV1/FVC) o0.70. BMI was categorized as underweight
(o20 kg/m2), normal weight (20–24.9 kg/m2), overweight (25.0–29.9 kg/m2), and obese
(X30.0 kg/m2).
Results: Interviews were completed in 5571 subjects from 6711 eligible individuals, and
spirometry was performed in 5314 subjects. There were 759 subjects with COPD and 4555
without COPD. Compared with the non-COPD group, there was a higher proportion of COPDElsevier Ltd. All rights reserved.
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COPD and body mass index 643subjects in the underweight and normal weight categories, and a lower proportion in the
obese category. Over one-half COPD subjects had BMI over 25 kg/m2. No differences in BMI
strata among countries were found in COPD subjects. Factors associated with lower BMI in
males with COPD were aging, current smoking, and global initiative for chronic obstructive
lung disease (GOLD) stages III–IV, whereas wheeze and residing in Santiago and Montevideo
were associated with higher BMI. In females with COPD, current smoking, lower education,
and GOLD stages II–IV were associated with lower BMI, while dyspnea and wheeze were
associated with higher BMI.
Conclusions: BMI alterations are common in COPD with no significant differences among
countries. Current smoking, age, GOLD stages, education level, residing in Santiago and
Montevideo, dyspnea and wheeze were independently associated with BMI in COPD.
& 2008 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) has been re-
defined1 to indicate that, apart from the deleterious effects
on the lungs, the disease is associated with clinically
relevant extrapulmonary manifestations.2–11 Systemic con-
sequences now recognized as important features of the
disease contribute to exercise intolerance, decreased health
status, and increased mortality.7,12–19 Among the most
extensively studied systemic features are unexplained
weight loss, alterations in the body mass index (BMI) and
in body composition. Data from epidemiologic studies have
shown that the prevalence of COPD is higher in those
patients with lower BMI.20,21 In addition results from
longitudinal studies have shown that low BMI is an important
risk factor for subsequent development of COPD in men, for
increased FEV1 decline in the same gender and for having a
new exacerbation in patients hospitalized for severe
exacerbation.22–24 BMI has also been identified as an
independent prognostic factor for COPD, with a clear
association between decreased BMI and increased mortality,
both in clinical patient series and in subjects from a
population sample.1–3,18,19 Several studies indicate that
the prevalence of nutritional abnormalities increases from
20% in stable outpatients up to 35% in patients eligible for
pulmonary rehabilitation.25–27
To date, most studies concerning the prevalence of
nutritional depletion in COPD have been performed in
selected populations.26,28–33 In general they found that the
prevalence of nutritional depletion in COPD was high,
especially in females, and was not associated with lower
levels of airway obstruction. Despite the fact that nutri-
tional depletion has been associated with different deleter-
ious effects and important outcomes in patients with COPD,
little information is available regarding BMI alteration in
COPD patients from a multicenter population-based study
that includes spirometry.18,19 Population-based studies are
necessary because they represent more accurately the total
spectrum of patients with the disease, thus allowing
unbiased inferences. Furthermore, it is still unclear if BMI
alteration in COPD is associated with the severity of airflow
limitation or with other factors like gender, age, ethnicity,
education, employment, tobacco consumption, clinical
symptoms, and geographical variation.
The aims of this study were (a) to evaluate the
characteristics by BMI categories of the total populationand of subjects with COPD drawn from a multicenter
population-based survey conducted in five Latin American
cities and (b) to explore the possible factors that influence
BMI in COPD.Methods and materials
The Proyecto Latinoamericano de Investigacion en Obstruc-
cio´n Pulmonar (PLATINO) study was a population-based
epidemiologic study conducted in five Latin American cities:
Sa˜o Paulo (Brazil), Santiago (Chile), Mexico City (Mexico),
Montevideo (Uruguay), and Caracas (Venezuela).20 Com-
plete details of the methodology and detailed descriptions
of participation rates and sample characteristics have been
published elsewhere.20,34–36 Briefly, a two-stage cluster
sampling method was used at each site in order to obtain
a probability sample of households. All adults aged 40 or
older living in the selected households were invited to
participate. Exclusion criteria for the study were mental
illness and institutionalization. Approval was obtained from
the ethical committee of the institutions involved in the
study and written informed consent was obtained from each
subject.
Information was collected on several factors potentially
associated with COPD, including age, sex, ethnicity (self-
reported), smoking habits, years of formal education,
employment, respiratory symptoms, and prior spirometric
testing. Copies of the questionnaires are available at the
PLATINO website (http://www.platino-alat.org). A portable,
battery-operated, ultrasound transit-time-based spirometer
(Easy-OneTM; NDD Medical Technologies, Chelmsford MA and
Zu¨rich, Swizerland) was used to perform pulmonary function
testing. Calibration was checked daily with a 3-liter syringe.
Subjects performed up to 15 forced expiratory maneuvers
(average 5–6) to obtain three American Thoracic Society
(ATS) acceptable maneuvers, with forced vital capacity
(FVC) and forced expiratory volume in the first second (FEV1)
reproducible within 150 ml.37 Albuterol 200mcg was then
administered by inhalation through a 500-ml spacer, and
the test was repeated 15min later (average 4–5 maneuvers).
All spirometric examinations were carried out with the
subject seated, using a nose clip and a disposable mouth-
piece. Exclusions for spirometry included recent thoracic
or abdominal surgery, myocardial infarction, eye surgery
or retinal detachment, hospitalization for any cardiac
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120 beats per minute.
We used the definition of COPD proposed by the Global
Initiative for Chronic Obstructive Lung Disease (GOLD): a
ratio of the postbronchodilator FEV1 over FVC below 0.70.
2
This definition is consistent with the European Respiratory
Society and ATS directives.1 Anthropometric measure-
ments were taken. Height was measured with a portable
Secas stadiometer (precision 0.1 cm), using the technique
recommended by Lohman et al.38 Weight was measured
using an electric Tanitas scale (precision 200 g). The
analysis of nutritional status was based only on the
assessment of BMI. It was calculated as the ratio weight/
height2 (kg/m2) and categorized into four groups: under-Table 1 Description of the total population.
Variables Underweight
(n ¼ 186), n (%)
Normal
(n ¼ 1346), n
Age, years (mean7SD) 57.3713.9 55.4712.5
Age group, years
40–49 75 (40.3) 575 (42.7)
50–59 45 (24.2) 358 (26.6)
460 66 (35.5) 413 (30.7)
Gender
Male 78 (41.9) 553 (41.1)
Female 108 (58.1) 793 (58.9)
Ethnicity
White 99 (53.2) 757 (56.4)
Black 16 (8.6) 74 (5.5)
Asian 4 (2.2) 18 (1.3)
Mulatto 61 (32.8) 449 (33.5)
Indian 6 (3.2) 44 (3.3)
Education, years
(mean7SD)
6.874.5 7.975.0
Employment
Yes 92 (49.5) 771 (57.3)
No 94 (50.5) 574 (42.7)
Smoking, pack-years
(mean7SD)
17.8724.1 11.1717.4
Smoking, pack-years
0–10 91 (49.5) 847 (63.3)
10–20 34 (18.5) 203 (15.2)
X20 59 (32.1) 288 (21.5)
Smoking status
Never 57 (30.7) 499 (37.1)
Former 32 (17.2) 373 (27.8)
Current 97 (52.2) 472 (35.1)
Respiratory symptoms
Cough 43 (23.1) 281 (20.9)
Phlegm 41 (22.0) 241 (17.9)
Wheeze 45 (24.2) 261 (19.4)
Dyspnea 66 (36.5) 491 (36.8)
FVC, l (mean7SD) 3.371.0 3.571.0
FEV1, l (mean7SD) 2.570.8 2.770.8
FEV1/FVC (mean7SD) 74.3712.2 77.179.4
FEV1 ¼ forced expiratory volume in 1 s; FVC ¼ forced vital capacity;weight (o20.0 kg/m2), normal weight (20.0–24.9 kg/m2),
overweight (25.0–29.9 kg/m2), and obese (X30.0 kg/m2).39Statistical analyses
For descriptive analyses, differences between BMI groups
were tested using Pearson’s w2 for categorical variables and
Cuzick’s nonparametric test for trend among continuous
variables.40 Comparisons examining the distribution of BMI
categories were age-standardized and adjusted for survey
design using the SVY commands in STATA. Between-country
comparisons were also adjusted for multiple comparisons
using Bonferroni’s method. Multivariable linear regression(%)
Overweight
(n ¼ 2176), n (%)
Obese
(n ¼ 1606), n (%)
p-Value
56.9711.8 56.2710.8 0.001
o0.0001
756 (34.7) 543 (33.8)
644 (29.6) 539 (33.6)
776 (35.7) 524 (32.6)
o0.0001
975 (44.8) 496 (30.9)
1201 (55.2) 1110 (69.1)
0.016
1160 (53.5) 882 (53.9)
116 (5.4) 98 (6.1)
17 (0.8) 11 (0.7)
757 (34.9) 537 (33.6)
120 (5.5) 91 (5.7)
7.874.8 7.174.5 0.009
o0.0001
1242 (57.1) 814 (50.7)
934 (42.9) 792 (49.3)
10.3718.3 9.6719.9 o0.0001
o0.0001
1,494 (68.9) 1,188 (74.0)
297 (13.7) 152 (9.5)
379 (17.5) 265 (16.5)
o0.0001
918 (42.2) 788 (49.1)
597 (27.4) 466 (29.0)
661 (30.4) 352 (21.9)
428 (19.7) 356 (22.2) 0.250
415 (19.1) 297 (18.5) 0.536
476 (21.9) 486 (30.3) o0.0001
933 (43.3) 919 (58.0) o0.0001
3.471.0 3.270.9 o0.0001
2.770.8 2.570.7 o0.0001
77.878.4 79.377.3 o0.0001
SD ¼ standard deviation.
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continuous variable in persons with spirometric evidence of
airway obstruction. Regressions were adjusted for survey
design using the SVY: REGRESS command in STATA. All
analyses were performed with the STATA software package
(version 9.2; STATA Corporation, College Station, TX, USA
2006).Results
Complete interviews were achieved in 5571 subjects from a
total of 6711 eligible individuals, and spirometry was performed
in 5314 subjects. Among this population there were 759 subjects
with postbronchodilator FEV1/FVCo0.70 (COPD) and 4555 indi-
viduals with a postbronchodilator FEV1/FVCX0.70 (no COPD).
Descriptions of the total population and subjects with COPD
are presented in Tables 1 and 2, respectively. In the entireTable 2 Description of subjects with COPD.
Variables Underweight
(n ¼ 51), n (%)
Normal
(n ¼ 230)
Age, years (mean7SD) 65.7714.4 64.0712
Age group, years
40–49 7 (13.7) 39 (17.0
50–59 14 (27.5) 46 (20.0
460 30 (58.8) 145 (63.0
Gender
Male 22 (43.1) 130 (56.5
Female 29 (56.9) 100 (43.5
Ethnicity
White 28 (54.9) 146 (63.5
Black 5 (9.8) 11 (4.8)
Asian 1 (2.0) 6 (2.6)
Mulatto 16 (31.4) 59 (25.7
Indian 1 (2.0) 8 (3.5)
Education, years (mean7SD) 4.674.0 6.874.7
Employment
Yes 14 (27.5) 108 (47.0
No 37 (72.6) 122 (53.0
Smoking, pack-years (mean7SD) 26.1732.4 18.5722
Smoking, pack-years
0–10 21 (42.0) 106 (46.1
10–20 7 (14.0) 35 (15.2
X20 22 (44.0) 89 (38.7
Smoking status
Never 10 (19.6) 61 (26.5
Former 12 (23.5) 68 (29.6
Current 29 (56.9) 101 (43.9
Respiratory symptoms
Cough 17 (33.3) 78 (33.9
Phlegm 15 (29.4) 64 (27.8
Wheeze 17 (33.3) 80 (34.8
Dyspnea 19 (38.8) 100 (44.3
FVC, l (mean7SD) 3.170.9 3.571.1
FEV1, l (mean7SD) 1.870.6 2.270.8
FEV1/FVC (mean7SD) 57.279.8 61.379.1
FEV1 ¼ forced expiratory volume in one second; FVC ¼ forced vital cpopulation there were significant differences among the BMI
categories in age, gender, ethnicity, years of education,
employment, smoking status, spirometry values, and the
frequency of wheezing and dyspnea. As BMI increased, there
was a progressive decrease in current smoking status and
pack-years of smoking exposure, and a progressive increase in
the frequency of dyspnea and the mean FEV1/FVC ratio.
In the COPD population about 7% had underweight
(o20 kg/m2), 30% normal BMI (20–24.9 kg/m2), and 64%
overweight or obesity (X25.0 kg/m2). Comparisons among
the BMI categories showed that only gender, smoking status,
the frequency of wheezing and dyspnea, and FEV1/FVC ratio
were different in subjects with COPD. As BMI increased,
there was a progressive decrease in current smoking status,
and a progressive increase in the frequency of wheezing and
dyspnea, and in the mean FEV1/FVC ratio.
The proportions of subjects from the total population
with and without COPD by BMI categories (adjusted for age, n (%)
Overweight
(n ¼ 303), n (%)
Obese
(n ¼ 175), n (%)
p-Value
.9 64.8711.2 62.7712.4 0.217
0.126
) 33 (10.9) 30 (17.1)
) 70 (23.1) 49 (28.0)
) 200 (66.0) 96 (54.9)
0.024
) 168 (55.5) 77 (44.0)
) 135 (44.6) 98 (56.0)
0.178
) 207 (68.3) 108 (61.7)
15 (5.0) 8 (4.6)
2 (0.7) –
) 64 (21.1) 49 (28.0)
15 (5.0) 10 (5.7)
7.174.8 6.574.1 0.104
0.068
) 122 (40.3) 73 (41.7)
) 181 (59.7) 102 (58.3)
.3 19.2727.1 10.2732.7 0.014
0.242
) 156 (51.5) 102 (58.3)
) 43 (14.2) 20 (11.4)
) 104 (34.3) 53 (30.3)
o0.0001
) 106 (35.5) 62 (35.4)
) 97 (32.0) 70 (40.0)
) 100 (33.0) 43 (24.6)
) 90 (29.7) 53 (30.3) 0.736
) 88 (29.0) 48 (27.4) 0.977
) 111 (36.6) 87 (49.7) 0.009
) 149 (49.2) 111 (65.3) o0.0001
3.471.0 3.371.1 0.542
2.270.7 2.170.7 0.288
62.178.5 79.377.3 o0.0001
apacity; SD ¼ standard deviation.
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M. Montes de Oca et al.646and survey design) are shown in Figure 1. The proportion of
subjects without COPD progressively increased from the
underweight to obese categories, whereas the proportion of
COPD subjects progressively decreased (po0.0001). The BMI
categories by COPD status are shown in Figure 2. There was
a higher proportion of COPD subjects in the underweight and
normal-weight categories compared to non-COPD subjects,
whereas in the obese category the proportion of subjects
without COPD was higher and a similar trend was observed in
the overweight category (p ¼ 0.07). In others words, the
proportion of COPD subjects progressively increased as BMI
decreased.100
80
60
40
20
0
Underweight Normal
%
Non-COP
Figure 1 Proportion of the study population with and without
(po0.0001).
50
40
30
20
10
0
Underweight Normal
%
Figure 2 BMI categories by COPD status *po0.0001 (
Table 3 BMI categories by countries in the COPD population.
BMI categories Sao Paulo % (SE) Santiago % (S
Underweight (o20 kg/m2) 12.36 (2.97) 4.31 (1.60
Normal (20–24.9 kg/m2) 33.17 (4.52) 27.18 (3.41
Overweight (25.0–29.9 kg/m2) 32.33 (4.22) 39.75 (4.26
Obese (X30.0 kg/m2) 22.13 (3.23) 28.76 (3.86
100 100
p40.05 (overall Bonferroni adjusted for each category).BMI strata by individual countries in the COPD group
(adjusted for age and survey design) are presented in
Table 3. No significant differences in BMI strata among
countries were found in the COPD population (p40.05).
Lung function in COPD subjects by BMI categories is shown
in Figure 3. Using the PLATINO36 predicted values, there was
a curvilinear relationship between BMI with FEV1 and FVC,
that allows us to speculate a possible effect of BMI on lung
function or vice versa.
Tables 4 and 5 present the regression models explaining
BMI among male and female subjects with COPD, respec-
tively. In males, aging, current smoking, and severe COPDOverweight Obese
D COPD
COPD, by BMI categories, adjusted for age and study design
Overweight Obese
Non-COPD
COPD
COPD vs. no COPD) ypo0.001 (COPD vs. no COPD).
E) Mexico City % (SE) Montevideo % SE) Caracas % (SE)
) 6.91 (3.55) 5.15 (2.92) 7.14 (2.14)
) 31.25 (6.95) 37.42 (5.52) 30.42 (3.66)
) 37.44 (7.62) 31.31 (5.28) 40.38 (4.33)
) 24.39 (6.12) 26.11 (5.52) 22.06 (3.51)
100 100 100
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Figure 3 Lung function in persons with COPD by BMI categories
using PLATINO predicted values.
Table 4 Regression model explaining BMI among male
subjects with COPD (n ¼ 397).
Coeffi-
cient
95% confidence
interval
p-Value
Age (per year) 0.07 0.12 0.03 0.001
Former smoker 0.61 0.49 1.71 0.278
Current smoker 1.64 2.87 0.42 0.009
GOLD stage II 0.52 0.50 1.53 0.317
GOLD stages III
and IV
2.92 4.74 1.11 0.002
Dyspnea 0.39 0.53 1.30 0.407
Wheeze 1.17 0.32 2.02 0.007
Cough 0.55 1.49 0.40 0.257
Phlegm 0.29 1.29 0.71 0.571
Santiago 1.64 0.34 2.94 0.013
Mexico City 1.34 0.23 2.90 0.095
Montevideo 1.44 0.14 2.73 0.030
Caracas 0.27 1.06 1.60 0.690
Educationo3
years
0.62 1.85 0.61 0.324
Constant 30.31 27.16 33.47 o0.001
Model R2 ¼ 0.1501.
Table 5 Regression model explaining BMI among female
subjects with COPD (n ¼ 343).
Coeffi-
cient
95% confidence
interval
p-Value
Age (per year) 0.02 0.08 0.03 0.409
Former smoker 0.09 1.60 1.41 0.902
Current smoker 3.13 4.49 1.77 o0.001
GOLD stage II 1.56 2.82 0.31 0.015
GOLD stages III
and IV
2.48 4.75 0.22 0.032
Dyspnea 2.42 1.24 3.59 o0.001
Wheeze 1.30 0.06 2.53 0.039
Cough 0.55 0.85 1.94 0.441
Phlegm 0.25 1.26 1.76 0.742
Santiago 1.14 0.66 2.94 0.214
Mexico City 0.77 2.74 1.20 0.444
Montevideo 0.64 1.12 2.40 0.476
Caracas 0.04 1.68 1.75 0.968
Educationo3
years
1.61 2.99 0.23 0.022
Constant 28.22 24.50 31.94 o0.001
Model R2 ¼ 0.1365.
COPD and body mass index 647(GOLD stages III and IV) were associated with lower BMI,
while wheeze and residing in Santiago and Montevideo were
associated with higher BMI, with the model explaining about
15% of variation in BMI. In females, current smoking, lower
education level (o3 years), and GOLD stages II–IV were
associated with lower BMI, whereas dyspnea and wheeze
were associated with higher BMI, with the model explaining
about 14% of variation in BMI.Discussion
The PLATINO study was designed to evaluate the prevalence
of COPD in five Latin American cities. However, the data
offer a good opportunity to assess different aspects of thedisease in a population-based sample. We found a progres-
sive increment in the proportion of COPD subjects as BMI
decreased, with the converse in subjects without COPD.
Compared with non-COPD subjects the proportion of COPD
subjects in the underweight and normal-weight categories
were higher, whereas in the obese category was lower. In the
COPD population the overall age-adjusted differences in BMI
strata were not different among countries. The factors
associated with lower BMI in male COPD subjects were
aging, current smoking, and GOLD stages III and IV while
wheeze and residing in Santiago and Montevideo were
associated with higher BMI. In females with COPD, current
smoking, lower education and GOLD stages II–IV were
associated with lower BMI, whereas dyspnea and wheeze
were associated with higher BMI.
During the last decade the influence of the BMI on
different epidemiologic and functional aspects of COPD has
become an area of increasing research interest. Several
studies have documented a clear association between low
BMI with poor prognosis and mortality in patients with
established COPD.7,18,19,31,33 Additionally, there is evidence
suggesting that COPD prevalence increases as BMI decreases
and that low BMI increases FEV1 decline and subsequent risk
for getting COPD.7,18,19,31,33
Nutritional depletion has been commonly reported in
COPD patients.18,19,26–28 The prevalence of nutritional
depletion in outpatient COPD populations by body composi-
tional analysis varied from 20% to 45%.26,27 In moderate-to-
severe COPD patients recruited from out-patient centers,
Vermeeren et al.27 reported that 73% had normal BMI and
normal fat-free mass index (FFMI), 15% normal BMI and low
FFMI, 1% low BMI and normal FFMI and 11% low BMI and low
FFMI. On the other hand, using data on patients with COPD
identified in an epidemiologic study, Vestbo et al.19 showed
that 83.8% had normal or high BMI and FFMI above the 10th
ARTICLE IN PRESS
M. Montes de Oca et al.648percentile, 13.1% normal or high BMI and FFMI below the
10th percentile, 0.7% low BMI and FFMI above the 10th
percentile, and 2.4% low BMI and FFMI below the 10th
percentile.
To our knowledge, no previous assay has examined the
characteristics of a COPD population by BMI categories from
an international multicenter population-based study. Our
results indicate that in COPD subjects the FEV1/FVC ratio,
wheezing and dyspnea progressively increased from under-
weight to obese category, whereas the proportion of current
smokers progressively decreased as BMI increase. We also
found that compared with non-COPD population there was
higher proportion of COPD subjects falling in the underweight
and normal-weight categories. However, the analysis of the
total COPD population shows that 93% of them had normal or
high BMI (420 kg/m2). This is in agreement with Vestbo et al.,
who reported that 96.9% of the COPD population had normal
or high BMI.19 Compared with the studies of outpatients the
prevalence of COPD patients with low BMI was found to be
much lower in our study.25–33 These differences may be due
by the source of the populations studied; both our study and
Vestbo’s19 included patients with COPD identified in a
population survey, whereas the others included patients
from either small or selected populations. Data from these
latter studies usually included a higher proportion of
symptomatic patients and those with advanced COPD stages
than do studies based on a large unselected population.
The other important aspect assessed in the present study
was the analysis of the COPD population by BMI strata in five
different cities. Geographical and regional variations in BMI
have been reported in the general population.41,42 Some of
the studies indicate that these variations are partly
explained by illiteracy, sedentary lifestyle, and, to a lesser
extent by energy intake. To our knowledge no previous study
has evaluated geographical variations of BMI in COPD. We
found that, in subjects with COPD, the overall differences in
BMI categories were not significant among countries
(p40.05). These results do not support the geographical
influence in the BMI of COPD subjects; however the results
of regression models for factors explaining BMI in COPD
suggest that, after adjustment for other factors, residing in
Santiago and Montevideo was associated with higher BMI in
males. It is possible that the evaluation of several
geographical regions better reflects the global reality of
the BMI stratum of subjects with COPD.
Several studies have assessed the factors associated with
nutritional status in selected COPD populations.8,19,25,27–30
Some of these have suggested a relationship between
malnutrition, impaired pulmonary status and female gender.
Individuals with low weight have more hyperinflation, lower
diffusing capacity, and lower exercise capacity.25,29,30
Recent reports have suggested a relationship between
unexplained weight loss and various mediators of inflamma-
tion.8 Little information is available regarding the factors
influencing BMI in a population-based sample of persons with
COPD. The study of Vestbo et al indicated that BMI
decreased with increasing COPD severity, in particular in
women.19 Our results showed that age, current smoking,
dyspnea, wheeze, GOLD stages, education level and residing
in Santiago and Montevideo were the main factors influen-
cing BMI among COPD subjects. In addition they suggested
that, using locally derived reference values, an importantassociation exists between the BMI and lung function in
COPD. The influence of others factors such as gender and
smoking consumption on the nutritional state are well
established. It is worth noting that our models for both
genders had a relatively low predictive ability, suggesting
that other factors (e.g. not measured in PLATINO) may have
an even greater effect on BMI in COPD. The lack of previous
information about this issue in other multicenter popula-
tion-based studies makes it difficult to make comparisons
with our results.
The knowledge of the COPD prevalence by BMI categories
and the factors that influence the BMI in these patients is
very important because they may help to better understand
the important association between BMI with COPD morbidity
and mortality and also because some of them are amenable
to intervention.
Finally, there are some limitations of the present study
that deserve to be discussed. First, because of the
characteristics of the PLATINO study, our definition of COPD
was based on postbronchodilator FEV1/FVCo0.70 at a single
examination. Although this is the most widely accepted
definition for COPD, it represents a simplified case definition
for epidemiological purposes and not a definitive clinical
diagnosis. Second, the analysis of nutritional status was based
only on the assessment of BMI. Although BMI is a marker with
a widely accepted prognostic value and a well-known
association with morbidity outcomes in COPD, other measures
such as body composition have been recommended to
evaluate nutritional condition in these patients. Because of
the design of the PLATINO study, these types of analyses could
not be obtained; therefore it is likely that our results may
tend to underestimate the true rate of nutritional depletion
in COPD, and in the entire population as well. Third, this is a
cross sectional looking at a population at a given point in time
and not a longitudinal study. Therefore it only provides the
frequency and characteristics of the disease in this population
taking place when the study was conducted. It is possible that
higher mortality among COPD subject with the lowest BMI
causes a selection effect–if so, this would tend to under-
estimation of the observed effects.
In summary, the results of this study indicate that the
proportion of persons with COPD progressively increased as
BMI decreased. In addition compared with the non-COPD
group, the proportion of COPD subjects in the underweight
and normal-weight categories were higher, while in the obese
category was lower. However, even among persons with COPD,
more than half have a high BMI. No differences in BMI strata of
COPD subjects were found among the countries. Current
smoking, age, GOLD stages, education level, residing in
Santiago and Montevideo, dyspnea and wheeze were inde-
pendently associated with BMI in persons with COPD.
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